Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-0.66% $1.500
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2.37 mill |
EPS: | -16.19 |
P/E: | -0.0900 |
Earnings Date: | Apr 10, 2024 |
SharesOutstanding: | 1.578 mill |
Avg Daily Volume: | 1.193 mill |
RATING 2024-04-18 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Neutral | |
P/E: | Buy | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
Asset | n/a | n/a | n/a | n/a | ||
Debt | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0900 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.02x |
Company: PE -0.0900 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.191 - 1.809 ( +/- 20.60%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2008-05-08 | Carter Stephen | Sell | 10 000 | Common Stock |
2008-05-08 | Lokay Kevin G | Sell | 185 439 | Common Stock |
2008-05-08 | Lokay Kevin G | Sell | 100 000 | Options to Purchase Common Stock |
2008-05-08 | Mollica Joseph A | Sell | 10 000 | Common Stock |
2007-11-13 | Lokay Kevin G | Buy | 500 000 | Options to purchase Common Stock par value $0.01 |
INSIDER POWER |
---|
0.00 |
Last 33 transactions |
Buy: 1 218 228 | Sell: 315 439 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.500 (-0.66% ) |
Volume | 0.0234 mill |
Avg. Vol. | 1.193 mill |
% of Avg. Vol | 1.961 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:33 | buy | $1.860 | N/A | Active |
---|
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.